SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

               --------------------------------------------------

                                    FORM 10-Q

                   Quarterly Report Under Section 13 or 15(d)
                                     of the
                             Securities Act of 1934

                         FOR QUARTER ENDED JUNE 30, 2001
                         Commission File Number 0-12248

                                DAXOR CORPORATION

                    (Exact Name as Specified in its Charter)


             New York                                    13-2682108
(State or Other Jurisdiction of                       (I.R.S. Employer
Incorporation or Organization)                       Identification No.)

                                  350 Fifth Ave
                                   Suite 7120
                            New York, New York 10118

               (Address of Principal Executive Offices & Zip Code)

Registrant's Telephone Number:                    (212) 244-0555
     (Including Area Code)

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required by Section 13 or 15(d) of the  Securities  Exchange  Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

               Yes   X                No
                   -----                 -----

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

         CLASS                              OUTSTANDING AT JUNE 30,2001
-----------------------------------------------------------------------
         COMMON STOCK
PAR VALUE: $.01 per share                            4,664,909


<PAGE>



PART I.   FINANCIAL INFORMATION


ITEM 1.   FINANCIAL STATEMENTS                                              PAGE

          Consolidated Balance Sheet as at June 30, 2001 and
                   Balance Sheet as at December 31, 2000                    F-1


          Consolidated Statements of Income for the
                   Three and Six Months ended June 30,2001 and 2000         F-2

          Consolidated Statement of Cash Flows for the Six Months
                   ended June 30, 2001 and 2000                             F-3


          Notes to Consolidated Financial Statements (Unaudited)            F-4


PART II.  OTHER INFORMATION

ITEM 1.   LEGAL PROCEEDINGS

ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS; RESULTS OF OPERATIONS AND
          FINANCIAL CONDITION



<PAGE>


Part II OTHER INFORMATION

Item 1.
Legal Proceedings

None

                      MANAGEMENT'S DISCUSSION AND ANALYSIS
             RESULTS OF OPERATIONS AND FINANCIAL CONDITION

ITEM 2.

RESULTS OF OPERATIONS

Three months ended June 30, 2001 as compared with three months ended June 30,
2000.

     For the three months ended June 30, 2001 total revenues were  $679,558,  up
from  $640,043  in 2000.  Operating  revenues  were  $138,917  in 2001 down from
$150,438 in 2000.  Dividend  income was $465,246 with a net interest  expense of
$35,174 in 2001, as compared to dividend  income of $466,051 with a net interest
expense of $55,092 in 2000.  In 2001,  the  Company  had a net income of $93,713
before  income taxes versus a net loss of $61,761  before  income taxes in 2000.
The Company  anticipates  that it's sales of equipment  and kits will become the
major  source of income for the  Company.  The Company is  currently  initiating
distribution networks.

Six months ended June 30, 2001 as compared with six months ended June 30, 2000.

     For the six months ended June 30, 2001, total revenues were $1,327,214 down
from $1,357,779 in 2000.  Operating revenues were $278,994 down from $361,997 in
2000.  Dividend income was $939,165 with a net interest  expense of $69,583,  as
compared to the  dividend  income of  $939,545  with a net  interest  expense of
$100,174 in 2000. In 2000,  the Company had $6,005 in capital gains vs $9,731 in
2001.  In 2001,  the Company had a net income of $157,816  before  income  taxes
versus  $33,592  before  income  taxes in 2000.  Operations  income  in 2000 was
greater than in 2001  because of direct  sales of the  BVA-100.  The company has
adopted a policy  that  encourages  leasing or renting  of  equipment  to enable
hospitals  to test the  equipment.  This  results in a sale of kits but a slower
recognition of operating income, from BVA sales.

LIQUIDITY AND CAPITAL RESOURCES

     At June 30,  2001 the  Company had total  assets of  $48,207,158  and total
liabilities of $10,538,927 with shareholders' equity of $37,668,231. The Company
has a net pre-taxed  unrealized gain of $24,781,146 and $16,355,556 of net after
tax unrealized capital gains on available-for-sale  securities in its portfolio.
This amount is included in the calculation of Total  Shareholders'  Equity.  The
Company's  stock  portfolio had a market value of  $47,271,440  with  short-term
loans of $1,985,679 with 4,664,909 shares outstanding.

     The Company has adequate  resources for the current  marketing level of its
Blood  Volume  Analyzer  as well as capital to sustain its  localized  semen and
blood banking  services.  The Company is reviewing  various options in regard to
establishing a nationwide sales force as opposed to utilizing  independent local
dealer  distribution  networks  for  marketing  the Blood Volume  Analyzer.  The
Company is  currently  negotiating  a possible  agreement in the near future for
distribution  of  the  Blood  Volume  Analyzer  in  Japan.  The  Company  has an
instrument  loaner  reagent plan which  requires use of the Company's  reserves.
Under a sale or a lease plan,  the Company  receives  income  immediately on its
equipment.  The equipment  loaner  reagent plan permits a user to make a minimal
initial  capital  commitment.  This  results  in  a  slower  return  on  capital
expenditure  for the  Company.  The Company is currently  leasing its  equipment
directly. If the leasing program becomes more widely accepted,  then the Company
will attempt to arrange for leases through


<PAGE>

independent leasing companies,  to whom it will sell the BVA-100. The Company is
evaluating blood volume instrumentation management programs for hospitals. Under
such a plan, the Company would provide equipment and personnel on a sub-contract
basis.  The  Company  will use its  current  financial  reserves  primarily  for
developing  and marketing the Blood Volume  Analyzer.  The Company is evaluating
various options to expand blood banking  services in conjunction with the use of
the Blood Volume Analyzer.

The Company did not file any reports on form 8-K.



<PAGE>

                                DAXOR CORPORATION
                              FINANCIAL STATEMENTS
================================================================================
DAXOR CORPORATION
CONSOLIDATED BALANCE SHEETS[UNAUDITED]

                                                      June 30,      December 31,
                                                        2001           2000
                                                        ----           ----
================================================================================
ASSETS

CURRENT ASSETS
Cash                                               $     44,240    $     18,439
Marketable Securities at Fair Value
June 30,2001 and  December 31,
2000. (Notes 1 and 2)                                47,271,440      48,722,403
Accounts receivable                                     147,876         107,927
Other current assets                                    404,505         363,758
                                                   ------------    ------------

Total Current Assets                                 47,868,061      49,212,527

EQUIPMENT AND IMPROVEMENTS
Storage tanks                                           125,815         125,815
Leasehold improvements, furniture
and equipment                                           837,457         836,813
Laboratory equipment                                    278,087         278,087
                                                   ------------    ------------
                                                      1,241,359       1,240,715
Less: Accumulated depreciation and amortization         942,452         919,414
                                                   ------------    ------------
Net equipment and improvements                          298,907         321,301

Other Assets                                             40,190          41,290

Total Assets                                       $ 48,207,158    $ 49,575,118
                                                   ============    ============

================================================================================
LIABILITIES AND SHAREHOLDERS' EQUITY
================================================================================

CURRENT LIABILITIES
Accounts payable and accrued liabilities           $    118,451    $     42,431
Loans payable (Notes 1 and 2)                         1,985,679       1,775,363
Other Liabilities                                         9,207          73,741
Deferred Taxes (Note 1)                               8,425,590       9,011,745
                                                   ------------    ------------
Total  Liabilities                                   10,538,927      10,903,280

SHAREHOLDERS' EQUITY
Common stock, par value $.01 per share:
Authorized 10,000,000 shares: issued and
outstanding shares 4,664,909 June 30,
2001 and 4,664,909  December 31, 2000                    53,097          53,097
Additional Paid in capital                            9,798,232       9,798,232
Net unrealized holding gains
on available-for-sale securities (Note 1)            16,355,556      17,493,387
Retained earnings                                    16,274,876      16,140,652
Treasury stock                                       (4,813,530)     (4,813,530)
                                                   ------------    ------------
Total Shareholders' Equity                           37,668,231      38,671,838

Total Liabilities and Shareholders' Equity         $ 48,207,158    $ 49,575,118
                                                   ============    ============


See accompanying notes to cosolidated financial statements


                                      F-1

<PAGE>

DAXOR CORPORATION
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
---------------------------------------------

<TABLE>
<CAPTION>
                                                                      THREE MONTHS ENDED                    SIX MONTHS ENDED
                                                                            JUNE 30                               JUNE 30

                                                                     2001              2000               2001              2000
                                                                     ----              ----               ----              ----
<S>                                                               <C>               <C>                 <C>               <C>
REVENUES:
------------------------------------------------------------------------------------------------------------------------------------
Operating revenues                                                $  138,917        $   150,438         $  278,994        $  361,997
Other revenues                                                        56,990             25,791             99,324            50,232
Dividend income                                                      465,246            466,051            939,165           939,545
Gains (losses) on sale
of securities                                                         18,435             (2,237)             9,731             6,005

Total Revenues                                                       679,588            640,043          1,327,214         1,357,779
                                                                  ----------        -----------         ----------        ----------

COSTS AND EXPENSES
------------------------------------------------------------------------------------------------------------------------------------
Operations of Laboratories                                           208,973            315,706            429,213           522,300
Selling, General, and
Administrative                                                       337,405            331,006            670,602           701,713
Interest expense, net of
interest income                                                       35,174             55,092             69,583           100,174
                                                                  ----------        -----------         ----------        ----------

Total Costs and Expenses                                             581,552            701,804          1,169,398         1,324,187
                                                                  ----------        -----------         ----------        ----------

Net Income (Loss) Before Income
Taxes                                                                 98,036            (61,761)           157,816            33,592

Provision for income taxes                                             4,323                 --             23,592             1,360
                                                                  ----------        -----------         ----------        ----------

Net Income (Loss)                                                 $   93,713        $   (61,761)        $  134,224        $   32,232
                                                                  ==========        ===========         ==========        ==========

Weighted Average Number of Shares
Outstanding                                                        4,664,909          4,679,242          4,664,909         4,682,409

Net Income or (Loss) per Common Equivalent
Share                                                             $     0.02        $     (0.01)        $     0.03        $     0.01
                                                                  ==========        ===========         ==========        ==========
</TABLE>

See accompanying notes to financial statements

                                       F-2
================================================================================


<PAGE>

DAXOR CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
FOR THE SIX MONTHS ENDED


                                                           JUNE 30,    JUNE 30,
                                                            2001         2000
                                                            ----         ----

------------------------------------------------------
CASH FLOWS FROM OPERATING ACTIVITIES
------------------------------------------------------
Net income or (loss)                                     $ 134,224    $  32,232
                                                         ---------    ---------
Adjustments to reconcile net income
(loss) to net cash provided by
operating activities:
Depreciation equipment and improvements                     23,038       28,664
(Gain) loss on sale of investments                          (9,731)      (6,005)
Change in assets and liabilities:
(Increase) decrease in accounts receivable                 (39,949)     (39,483)
(Increase) decrease in other current assets                (40,747)     181,206
(Increase) decrease in other assets                          1,100           --
Increase (decrease) in accounts payable,  accrued
and other liabilities net of "short sales"                  76,620      (74,058)
                                                         ---------    ---------

Total adjustments                                           10,331       90,324
                                                         ---------    ---------

Net cash provided by or (used in) operating activities     144,555      122,556
                                                         ---------    ---------

------------------------------------------------------
CASH FLOWS FROM INVESTING ACTIVITIES:
------------------------------------------------------
Payment for purchase of equipment and
improvements                                                  (644)      (2,900)
Net cash provided or (used) in purchase
and sale of investments                                   (330,876)    (160,578)
Net proceeds (repayments) of loans from
brokers used to purchase investments                       210,316      193,189
Proceeds from "short sales" not closed                       2,450       44,988
                                                         ---------    ---------
Net cash provided by or (used in) investing activities    (118,754)      74,699
                                                         ---------    ---------

------------------------------------------------------
CASH FLOWS FROM FINANCING ACTIVITIES:
------------------------------------------------------
Payment for purchase of treasury stock                          --     (228,413)

Net cash provided by or (used in) financing activities          --     (228,413)
                                                         ---------    ---------

Net increase (decrease) in cash and cash equivalents        25,801      (31,158)
Cash and cash equivalents at beginning of year              18,439       67,783
                                                         ---------    ---------

Cash and cash equivalents at end of period               $  44,240    $  36,625
                                                         =========    =========



See accompanying notes to financial statements

                                      F-3

<PAGE>

                                DAXOR CORPORATION

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

                     SIX MONTHS ENDED JUNE 30, 2001 AND 2000


     In the opinion of the  Company,  the  accompanying  unaudited  consolidated
financial  statements  contain  all  adjustments   (consisting  of  only  normal
recurring  accruals)  necessary to present  fairly the financial  position as of
June 30,2001, and December 31, 2000, the results of operations for the three and
six months  ended June  30,2001 and 2000 and cash flows for the six months ended
June  30,2001  and 2000.  The  consolidated  financial  statements  include  the
accounts  of the  Company  and  its  subsidiary.  All  significant  intercompany
transactions and balances have been eliminated in consolidation.


(1)  MARKETABLE SECURITIES

     Upon adoption of FASB No. 115, management has determined that the company's
portfolio is best  characterized as  "Available-For-Sale".  This has resulted in
the  balance  sheet  carrying  value  of  the  company's  marketable  securities
investments,  as of  June  30,  2001  and  December  31,  2000  being  increased
approximately  110.19 % and 119.30 % respectively  over its  historical  cost. A
corresponding  increase  in  shareholders'  equity  has  been  effectuated.   In
accordance with the provisions of FASB No. 115, the adjustment in  shareholders'
equity to reflect the  company's  unrealized  gains has been made net of the tax
effect  had these  gains been  realized.  The  following  tables  summarize  the
company's investments as of :


                                  June 30, 2001

<TABLE>
<CAPTION>
Type of security                     Cost                  Fair Value             Unrealized holding    Unrealized holding
----------------                     ----                  ----------             -------------------   ------------------
                                                                                       gains                  losses
                                                                                       -----                  ------
<S>                                <C>                      <C>                      <C>                      <C>
Equity                             $22,475,435              $47,270,540              $25,524,380              $729,275

Debt                                    14,859                      900                      -0-                13,959
                                   -----------              -----------              -----------              --------


Total                              $22,490,294              $47,271,440              $25,524,380              $743,248
                                   ===========              ===========              ===========              ========
</TABLE>


                                December 31, 2000

<TABLE>
<CAPTION>
Type of security                     Cost                  Fair Value             Unrealized holding    Unrealized holding
----------------                     ----                  ----------             -------------------   ------------------
                                                                                       gains                  losses
                                                                                       -----                  ------
<S>                                <C>                      <C>                      <C>                      <C>
Equity                             $22,202,412              $48,721,503              $27,425,484              $906,393
Debt                                    14,859                      900                        0                13,959
Total                              $22,217,271              $48,722,403              $27,425,484              $920,352
                                   ===========              ===========              ===========              ========
</TABLE>



                                      F-4

<PAGE>



     At June 30, 2001 the  securities  held by the Company had a market value of
$47,271,440  and a cost basis of $22,490,294  resulting in a net unrealized gain
of $ 24,781,146 or 110.19% of cost. At December 31, 2000 the securities  held by
the Company had a market value of  $48,722,403  and a cost basis of  $22,217,271
resulting in a net  unrealized  gain of  $26,505,132 or 119.30% of cost. At June
30, 1999 and December 31, 1998 marketable  securities,  primarily  consisting of
preferred and common stocks of utility companies, are valued at fair value .

(2)  LOANS PAYABLE

     As at  June  30,  2001  and  December  31,  2000,  the  Company  had  loans
outstanding  aggregating  $1,000,000 borrowed on a short term basis from a bank,
which are secured by certain  marketable  securities  of the Company.  The loans
bear interest at approximately 7.1875%.

     Short term margin debt due to brokers ,secured by the Companies  marketable
securities, totaled $985,679 at June 30, 2001 and $775,363 at December 31, 2000


                                      F-5